Nothing Special   »   [go: up one dir, main page]

MX2020005342A - Compuestos de pirazolopiridinona. - Google Patents

Compuestos de pirazolopiridinona.

Info

Publication number
MX2020005342A
MX2020005342A MX2020005342A MX2020005342A MX2020005342A MX 2020005342 A MX2020005342 A MX 2020005342A MX 2020005342 A MX2020005342 A MX 2020005342A MX 2020005342 A MX2020005342 A MX 2020005342A MX 2020005342 A MX2020005342 A MX 2020005342A
Authority
MX
Mexico
Prior art keywords
compounds
pyrazolopyridinone
pyrazolopyridinone compounds
fgfr
inhibitors
Prior art date
Application number
MX2020005342A
Other languages
English (en)
Inventor
Qian Liu
Zhao-Kui Wan
Luoheng Qin
Haibing Guo
Wing Shun Cheung
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2020005342A publication Critical patent/MX2020005342A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)

Abstract

La invención se refiere a nuevos compuestos de pirazolopiridinona, a composiciones farmacéuticas que comprenden dichos compuestos, a procesos para la preparación de dichos compuestos y al uso de dichos compuestos como inhibidores de FGFR (receptor del factor de crecimiento fibroblástico) y a su uso en el tratamiento de enfermedades, por ejemplo, el cáncer.
MX2020005342A 2017-11-24 2018-11-23 Compuestos de pirazolopiridinona. MX2020005342A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017112836 2017-11-24
PCT/CN2018/117296 WO2019101183A1 (en) 2017-11-24 2018-11-23 Pyrazolopyridinone compounds

Publications (1)

Publication Number Publication Date
MX2020005342A true MX2020005342A (es) 2020-10-14

Family

ID=66630494

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005342A MX2020005342A (es) 2017-11-24 2018-11-23 Compuestos de pirazolopiridinona.

Country Status (12)

Country Link
US (2) US11384099B2 (es)
EP (1) EP3717483B1 (es)
JP (1) JP7329510B2 (es)
KR (1) KR102723359B1 (es)
CN (1) CN111655689B (es)
AU (1) AU2018370904B2 (es)
BR (1) BR112020010004A2 (es)
CA (1) CA3084528A1 (es)
ES (1) ES2963339T3 (es)
MA (1) MA51221A (es)
MX (1) MX2020005342A (es)
WO (1) WO2019101183A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11691970B2 (en) * 2017-11-24 2023-07-04 Janssen Pharmaceutica Nv Pyrazolopyridinone compounds
JP2022515622A (ja) * 2018-12-26 2022-02-21 ヤンセン ファーマシューティカ エヌ．ベー． チエノピリジノン化合物
CN111454214B (zh) * 2020-05-27 2023-04-07 龙曦宁（上海）医药科技有限公司 一种2-甲氧基1-嘧啶乙胺盐酸盐的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221683A (en) 1984-03-19 1993-06-22 The Rockefeller University Diaminopyridine compounds and methods of use
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
AUPQ969800A0 (en) 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
AU2001293233A1 (en) 2000-09-01 2002-03-13 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
DK1650203T3 (da) 2000-09-11 2008-06-02 Novartis Vaccines & Diagnostic Quinolinonderivater som tyrosinkinaseinhibitorer
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
JP3539424B2 (ja) * 2002-07-24 2004-07-07 日産自動車株式会社 電気自動車の制御装置
EP2573079A3 (en) * 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
KR20050075005A (ko) 2002-11-13 2005-07-19 카이론 코포레이션 암을 치료하는 방법 및 관련 방법
WO2005047244A2 (en) 2003-11-07 2005-05-26 Chiron Corporation Inhibition of fgfr3 and treatment of multiple myeloma
US9029536B2 (en) 2010-08-04 2015-05-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds

Also Published As

Publication number Publication date
JP2021504332A (ja) 2021-02-15
CA3084528A1 (en) 2019-05-31
AU2018370904A1 (en) 2020-05-14
WO2019101183A1 (en) 2019-05-31
US20220340598A1 (en) 2022-10-27
US20210147446A1 (en) 2021-05-20
EP3717483B1 (en) 2023-09-06
ES2963339T3 (es) 2024-03-26
RU2020120796A (ru) 2021-12-24
EP3717483A4 (en) 2021-07-14
CN111655689B (zh) 2023-01-06
AU2018370904B2 (en) 2023-09-21
BR112020010004A2 (pt) 2020-10-13
CN111655689A (zh) 2020-09-11
KR20200090828A (ko) 2020-07-29
EP3717483A1 (en) 2020-10-07
KR102723359B1 (ko) 2024-10-28
US11384099B2 (en) 2022-07-12
JP7329510B2 (ja) 2023-08-18
MA51221A (fr) 2020-10-07

Similar Documents

Publication Publication Date Title
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
EA202090516A3 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX2018003563A (es) Nuevos compuestos.
MX2016014436A (es) Derivados de heterociclil-butanamida.
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MX2020000135A (es) Nuevos compuestos de quinolinona.
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2020005342A (es) Compuestos de pirazolopiridinona.
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
MX2018005515A (es) Derivados de 1,4-dicarbonil-piperidilo.
WO2018211324A8 (en) Prodrugs for the treatment of disease
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
MX2021007853A (es) Compuestos de tienopiridinona.
PH12018502139A1 (en) Phosphaplatin liquid formulations
MX2018003564A (es) 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer.